Research and Markets: Indication Broadening of Rituxan and Avastin will be the Key Growth Strategy for Genentech 2005-2011.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44581) has announced the addition of Datamonitor's new report: Genentech: PharmaVitae Profile to their offering. This analysis examines the historical and forecast performance for Genentech in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. Reasons to order your copy: -Benchmark Genentechs performance against key rivals in the ethical pharmaceutical sector -Understand Genentechs dominance of the monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing sector -Learn how indication broadening of Rituxan and Avastin will be the key growth strategy for Genentech 2005-2011 Summary of Contents: Chapter 1 Executive summary Key findings Historical and forecast ethical sales performance Therapeutic strategy Molecule type, externalization The ability to easily connect to and transfer information between business partners. Increasingly, information systems are designed to make their data available to outside partners and customers. This type of collaboration is expected to be a vital part of IT in the 21st century. See EDI. and geographic strategies Molecule type strategy Externalization strategy Geographic strategy Launch and expiry outlook SWOT analysis SWOT Analysis A tool that identifies the strengths, weaknesses, opportunities and threats of an organization. Chapter 2 Corporate history Background Key corporate developments Founding Genentechs first product Genentechs first mAb therapy Genentech timeline M&A history Genentechs history with its partner Roche Genentechs closest biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. peer seems to be following a growth by acquistion strategy Current corporate structure Current management team Chapter 3 Historical performance Revenue and growth rate analysis, 2002-05 Revenue and growth rate vs. peer set Product analysis, 2002-05 Growth drivers and resistors Operating revenue operating revenue Revenue from any regular source. Revenue from sales is adjusted for discounts and returns when calculating operating revenue. Compare other revenue. and cost analysis, 2002-05 Absolute P&L Historical perfomance against corporate goals Genentechs historical corporate goals Chapter 4 Forecast performance Key findings Revenue and growth rate analysis, 2005-11 Product analysis, 2005-11 Therapy area analysis, 2005-11 Therapy area focus Launch and expiries analysis, 2005-11 Launch portfolio Core portfolio Expiry portfolio Launch/core/expiry configuration Externalization analysis, 2005-11 Geographic analysis, 2005-11 Molecule type analysis, 2005-11 Chapter 5 Key products and competitors Key findings Oncology Avastin Newsflow Rituxan Herceptin Tarceva Insulated in·su·late tr.v. in·su·lat·ed, in·su·lat·ing, in·su·lates 1. To cause to be in a detached or isolated position. See Synonyms at isolate. 2. from Big Pharma and biotech competition Rituximab - monopoly on targeted NHL NHL Non-Hodgkin's lymphoma, see there market Domination of targeted breast cancer market Tykerb as potential long-term threat Tykerb is illustrative of small molecule vs. biologic threat in cancer Small molecule multi-targeted drugs provide potential competition Tarceva vs. Iressa - Genentech prevails over AstraZeneca Overview of key competition in oncology market AIID AIID Autoimmune and Inflammatory Disorders AIID Association des Infirmiers(ères) Intervenant(e)s en Diabétologie (Arthirits, Inflammation and Immune Disorders) Rituxan RA - Rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. Sales forecast - Rheumatoid arthritis Newsflow - Rheumatoid arthritis Competitive landscape - Rheumatoid arthritis AIID competitors Significant competition for Genentech Lucentis (ranibizumab) Sales forecast Newsflow Competitive landscape Significant opportunity for Genentech R&D pipeline R&D pipeline Chapter 6 Appendix IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. vs. company-reported data reconciliation 1 Abbreviations List of Tables For more information visit http://www.researchandmarkets.com/reports/c44581 Source: Datamonitor |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion